Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to human LKB1/STK11 serine/threonine kinase.|
|Purification||Ammonium sulfate precipitation|
|Storage buffer||PBS, pH 7.4|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control for this product is lung or uterus lysate.
Germline mutations of the LKB1 (STK11) tumor suppressor gene can lead to Peutz-Jeghers syndrome (PJS) and a marked predisposition to cancer. LKB1 encodes a serine/threonine kinase that is inactivated in PJS. The tumor suppressor protein PTEN is a LKB1-interacting protein. Several point mutations in LKB1 are associated with PJS and may disrupt the interaction with PTEN suggesting that the loss of this interaction might contribute to PJS. PTEN and LKB1 are predominantly cytoplasmic and nuclear, respectively, the interaction of the two leads to a cytoplasmic relocalization of LKB1. PTEN is a substrate of the kinase LKB1 invitro.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
liver kinase B1; LKB1; PJS; polarization-related protein LKB1; renal carcinoma antigen NY-REN-19; serine/threonine-protein kinase 11; serine/threonine-protein kinase LKB1
hLKB1; LKB1; PJS; STK11